Modulation of the production of reactive oxygen species by pre-activated neutrophils by aminoadamantane derivatives

Biochemical Pharmacology

Volumn 56, Issue 1, 1998, Pages 141-152

  Albrecht Goepfert, Evelyn ^a   Schempp, Harald ^a   Elstner, Erich F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aminoadamantanes; Morbus Alzheimer; Morbus Parkinson; Polymorphonuclear leukocytes; Reactive oxygen species; Respiratory burst

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; ANTIOXIDANT; CALCIMYCIN; ETHYLENE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; MEMANTINE; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ZYMOSAN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DEGRANULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIPID PEROXIDATION; NEUTROPHIL; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY BURST;

ALPHA 1-ANTITRYPSIN; AMANTADINE; AMINO ACIDS; AMINO ACIDS, CYCLIC; ANIMALS; ANTIOXIDANTS; ETHYLENES; LIPID PEROXIDATION; MEMANTINE; NEUTROPHIL ACTIVATION; NEUTROPHILS; OXIDATION-REDUCTION; PEROXIDASE; PIPERAZINES; REACTIVE OXYGEN SPECIES; SWINE;

EID: 0031752023     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00024-0     Document Type: Article

References (62)

1. Pantev M, Ritter R and Görtelmeyer R, Clinical and behavioural evaluation in long-term care patients with mild and moderate dementia under memantine treatment. Z Gerontol Psychiat 6: 103-117, 1993.
2. Schreiber H and Kornhuber HH, Das Parkinson Syndrom, Münch Med Wschr 134: 302-305, 1994.
3. Brenner M, Haass A, Jacobi P and Schimrigk K, Amantadine sulphate in treating Parkinson's disease: Clinical effects, psychometric tests and serum concentrations. J Neurol 236: 153-156, 1989.
4. Skuza G, Rogoz Z, Quack G and Danysz W, Memantine, adamantine and L-deprenyl potentiate the action of 1-DOPA in monoamine-depleted rats. J Neural Transm (Gen Sect) 98: 57-67, 1994.
5. Deshpande SS, Smith CD and Filbert M, Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. Arch Toxicol 69: 384-390, 1995.
6. Schneider E, Fischer PA, Clemens R, Balzereit F, Fünfgeld E-W and Haase AJ, Wirkungen oraler Memantin-Gaben auf die Parkinson-Symptomatik, Dtsch Med Wschr 109: 987-990, 1984.
7. Lupp A, Jackisch R, Lücking CH and Feuerstein TJ, Effects of the antiparkinsonian drugs amantadine and memantine on striatal transmitter release in vitro. Arch Pharmacol 342: 86-89, 1990.
8. Klee MR, Effect of memantine on membrane properties and postsynaptic potentials in neurons of Aplysia californica. Arzneim Forsch 32: 1259-1267, 1982.
9. Netzer R, Memantine reduces repetitive action potential firing in spinal cord nerve cell cultures. Europ J Pharm 186: 149-156, 1989.
10. Dimpfel W, Effects of memantine on synaptic transmission in the hippocampus in vitro. Arzneim Forsch/Drug Res 45: 1-5, 1995.
11. Osborne NN and Quack G, Memantine stimulates inositol phosphate production in neurones and nullifies N-methyl-D-aspartate-induced destructions of retinal neurons Neurochem Int 21: 329-336, 1992.
12. Bormann J, Memantine is a potent blocker of N-methyl-D-aspartate(NMDA) receptor channels. Europ J Pharmacol 166: 591-592, 1989.
13. Dawson VL and Dawson TM, Free radicals and neuronal death. Cell-Death Differ 3: 71-78, 1996.
14. Kruedener S, Schempp H and Elstner EF, Gas chromatographic differentiation between myeloperoxidase activity and Fenton-type oxidants. Free Rad Biol Med 19: 141-146, 1995.
15. Youngman JR and Elstner EF, Primary photodynamic reactions occurring during the breakdown of photosynthetic pigments. Ber Deutsch Bot Ges 96: 357-364, 1983.
16. Tang YW and Bonner T, The enzymatic inactivation of indoleacetic acid. 1. Some characteristics of the enzyme contained in pea seedlings. Arch Biochem Biophys 13: 11-25, 1947.
17. Heath OVS and Clark JE, Chelating agents as plant growth substances. Nature 177: 1118-1121, 1965.
18. Volpert R, Osswald W and Elstner EF, Effects of cinnamic acid derivatives on indole acetic acid oxidation by peroxidase. Phytochemistry 38: 19-22, 1995.
19. McNally JA and Bell AL, Myeloperoxidase-based chemiluminescence of polymorphonuclear leukocytes and monocytes. J Biolumin Chemaumin 11: 99-106, 1996.
20. Matheson NR, Wong PS and Travis J, Enzymatic inactivation of human alpha-1-protease inactivation by neutrophil myeloperoxidase. Biochem Biophys Res Comm 88: 402-409, 1979.
21. Moreno JJ and Pryor WA, Inactivation of alpha-1-proteinase inhibitor by peroxynitrite. Chem Res Tox 5: 425-431, 1992.
22. Elstner EF and Konze JR, Effects of point freezing on ethylene and ethane production by sugar beet leaf discs. Nature 263: 351-352, 1976.
23. Konze JR and Elstner EF, Ethane and ethylene formation by mitochondria as indication of aerobic lipid degradation in response to wounding of plant tissue. Biochim Biophys Acta 528: 213-221, 1978.
24. Hippeli SC and Elstner EF, Influence of diesel soot particles and sulfite on functions of polymorphonuclear leukocytes. Free Rad Res Comm 11: 29-38, 1990.
25. Albrecht-Goepfert E, Immunomodulatorische Eigenschaften von Adamantan Derivaten. Dissertation, TU München, ISBN 3-928536-69-9, 1996.
26. Bors W, Saran M, and Elstner EF, Screening for plant antioxidants. In: Plant Toxin Analysis; Modern Methods of Plant Analysis, New Series 13 (Eds. Linskens HF and Jackson JF), pp. 277-295. Springer Verlag, Berlin-Heidelberg-New York, 1992.
27. Meyer B, Schneider W and Elstner EF, Antioxidative properties of alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidabo virgaurea. Arzneim Forsch/Drug Res 45: 174-176, 1995.
28. Elstner EF, Der Sauerstoff. Biochemie, Biologie, Medizin. BI. Wiss.verlag Mannheim, 1990.
29. nd ed., 1989.
30. Turner JD, Beyreuther K and Theuring F, Alzheimer's Disease, Ernst Schering Research Foundation Workshop 17. Springer Verlag, Berlin-Heidelberg-New York, 1996.
31. Schönberg BS, Kokmen E and Okazaki H, Alzheimer's disease and other dementing illnesses in a defined United States population: incidence rates and clinical features. Ann Neurol 22: 724-729, 1987.
32. ++- release. TIPS 16: 356-359, 1995.
33. Götz ME, Dirr A, Burger R, Rausch WD and Riederer P, High dose selegiline augments striatal ubiquinol in mouse: An indication of decreased oxidative stress or of interference with mitochondrial respiration? A pilot study. J Neural Transm (Suppl.) 46: 149-156, 1995.
34. Harris ME, Carney JM, Cole PS, Hensley L and Howard BJ, β-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. NeuroReport 6: 1875-1879, 1995.
35. Good PF, Werner P, Hsu A, Olanow CW and Perl DP, Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149: 21-28, 1996.
36. Noursharg S, Mechanisms of neutrophil and eosinophil accumulation in vivo. Am Rev Respir Dis 148: 560-564, 1993.
37. Klebanoff SJ, Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 93: 480-489, 1980.
38. Babior BM, The respiratory burst of phagocytes. J Clin Invest 73: 599-601, 1984.
39. Janoff AJ, Elastase in tissue injury. Annu Rev Med 36: 207-216, 1985.
40. Clark RSB, Schiding JK, Kaczorowski SL, Marion DW and Kochanek PM, Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma 11: 499-506, 1994.
41. Matsuo Y, Ondera H, Shiga Y, Nakamura M and Ninomiya M, Correlations between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Stroke 25: 1469-1475, 1994.
42. Kuhn W and Müller T, Neuroimmune mechanisms in Parkinson's disease. J Neural Transm (Suppl.) 46: 229-233, 1995.
43. Mast H, Tatemichi TK and Mohr JP, Chronic brain ischemia: the contributions of Otto Binswanger and Alois Alzheimer to the mechanism of vascular dementia. J Neurolog Sci 132: 4-10, 1995.
44. Brun A and Englund E, A white matter disorder in dementia of Alzheimer type: A pathoanatomical study. Ann Neurol 19: 253-262, 1986.
45. Van Furth R, Current view on the mononuclear phagocyte system. Immunobiology 161: 178-185, 1982.
46. Streit WJ and Kincaid-Colton CA, The brain's immune system. Sci Am 11: 38-43, 1995.
47. Hu S, Chao CC, Khanna KV, Gerker G, Peterson PK and Molitor TW, Cytokine and free radical production by porcine microglia. Clin Immunol Immunopath 78: 93-96, 1996.
48. Kalaria RN, The immunopathology of Alzheimer's disease and some related disorders. Brain Pathol 3: 333-347, 1993.
49. McGeer PL and McGeer EG, The inflammatory response system of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Res Rev 21: 195-218, 1995.
50. Parpura V, Liu F, Brethorst S, Jeftinija K and Haydon PG, A-labratoxin stimulates glutamate release from cortical astrocytes in cell cultures. FEBS Lett 360: 266-270, 1995.
51. Westergaard N, Sonnewald U and Schousboe A, Metabolic trafficking between neurons and astrocytes: The glutamate glutamine cycle revisited. Develop Neurosci 17: 203-211, 1995.
52. Langeveld CH, Jongenelen AM, Schiepens E, Stoof JC, Bast A and Druckarch B, Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. Neurosci Lett 192: 13-16, 1995.
53. Havlichek DH, Antiviral drugs. In: Human Pharmacology, (Eds. Wingard LB, Brody TM, Larner J and Schwartz A), p. 30. Mosby Year Book, St. Louis, MO, 1991.
54. Honegger UE, Quack G and Wiesmann UN, Evidence for lysosomotropism of memantine in cultured human cells: Cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharma Toxic 73: 202-208, 1994.
55. Berridge MJ and Irvine RF, Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 312: 315-321, 1984.
56. Majerus PW, Inositol phosphate biochemistry. Annu Rev Biochem. 61: 225-250, 1992.
57. Coté GG and Grain RC, Biochemistry of phosphoinositides. Annu Rev Plant Physiol Plant Mol Biol 44: 333-356, 1993.
58. Hallch LM and Sherman WR, The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 255: 10896-10901, 1980.
59. 2+-mobilizing inhibitors of D-myo-inositol 1,4,5-triphosphate 5-phosphatase. J Med Chem 37: 907-912, 1995.
60. Manji HK, Potter WZ and Lenox RH, Signal transduction pathway. Arch Gen Psychiatry 52: 531-543, 1995.
61. DelRio E, Nicholls DG and Downes CP Characterization of the effects of lithium and inositol on phosphoinositide turn-over in cerebellar granule cells in primary culture. J Neurochem 66: 517-524, 1996.
62. + channels as targets for neuroprotective drugs. TIPS 16: 309-316, 1995.